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Abstract: Hypertension is one of the main risk factors for the development of cardiovascular 
diseases and the search for new therapeutic strategies aimed at optimizing its control remains 
an ongoing research and clinical challenge. In recent years, there has been a marked increase in 
the use of combinations of antihypertensive drugs with complementary mechanisms of action, 
with the aims of reducing blood pressure levels more rapidly and vigorously than strategies 
employing monotherapy and improving treatment compliance and adhesion. Therefore, as 
recommended by the 2009 reappraisal of the European Society of Hypertension/European 
Society of Cardiology Guidelines, the use of a triple combination that combines a calcium 
channel blocker, an angiotensin II receptor blocker and a thiazide diuretic seems a reasonable 
and efficacious combination for the management of hypertensive patients with moderate, high 
or very high risk. This article reviews the clinical trials carried out with the fixed combina-
tion of amlodipine/valsartan/hydrochlorothiazide at the doses recommended for each drug in 
monotherapy. The data show that this combination achieved greater reductions in mean sitting 
diastolic and systolic blood pressure than amlodipine, valsartan or hydrochlorothiazide in mono-
therapy, with favorable pharmacodynamic and pharmacokinetic profiles. The triple combination 
at high single doses should be used with caution in elderly patients and those with renal or 
liver failure. Although the tolerability and safety of the triple combination are good, the most-
frequently reported adverse effects were peripheral edema, headache and dizziness. Analytical 
alterations were consistent with the already-known biochemical effects of amlodipine, valsartan 
or hydrochlorothiazide in monotherapy. In summary, triple-therapy with amlodipine/valsartan/ 
hydrochlorothiazide in a single pill contributes additional advantages to fixed -combinations 
of two drugs, achieving a greater and more rapid reduction in blood pressure levels in a safe, 
well-tolerated manner.
Keywords: hypertension treatment, antihypertensive fixed-dose triple-therapy, blood pressure 
control
Introduction
Hypertension affects millions of people worldwide and in developed countries the 
progressive aging of the population is increasing its prevalence even more. Hyperten-
sion is a determining risk factor for the development of cardiovascular diseases such 
as myocardial infarction, stroke, renal disease and heart failure and correct blood 
pressure (BP) control reduces cardiovascular morbidity and mortality.1 However, in 
spite of the many therapeutic options available and the social and health consequences 
associated with inadequate BP control, only one-third of hypertensive patients achieve 
correct BP levels according to their total cardiovascular risk.1
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Because the etiopathogenesis of hypertension is 
 multifactorial, most patients require more than one antihy-
pertensive drug to achieve correct BP control2 and the most 
common therapeutic strategy is a fixed or free combination 
of two antihypertensive drugs.3 In patients with high or very 
high cardiovascular risk, such as diabetics or those with renal 
failure, a combination of three or more antihypertensive drugs 
with differing mechanisms of action is required to reach the 
BP objective recommended by the European Guidelines on 
Hypertension (BP  130/80).4 The use of antihypertensive 
combinations with complementary mechanisms of action 
results in greater BP reductions than those achieved by the 
sum of each drug in monotherapy. Therefore, the European 
guidelines consider the combined use of a calcium channel 
blocker, an angiotensin II receptor blocker and a thiazide 
diuretic a reasonable combination4 for patients with very-high 
baseline BP values or those at high cardiovascular risk.
Calcium channel blockers prevent the entry of calcium 
to the cellular cytosol in arteriolar smooth muscle cells. 
Angiotensin II receptor blockers impede the activation of 
angiotensin II AT
1
 receptors, preventing the vasoconstriction 
induced by angiotensin II, while blockade of the receptor in 
the renal cells helps prevent the renal retention of sodium. 
Thiazide diuretics reduce intravascular volume and total 
body sodium. The final effect of the combination of these 
three different mechanisms of action not only provides 
antihypertensive synergy but simultaneously counteracts 
or attenuates the possible adverse effects of each drug in 
monotherapy, particularly the hypokalemia induced by the 
diuretic and the peripheral edema induced by the calcium 
antagonist. The different available fixed combinations of 
valsartan/hydrochlorothiazide (HCTZ) and valsartan/amlo-
dipine have been shown to be efficient and safe in reducing 
BP levels in patients in whom monotherapy is not sufficient to 
achieve BP control.5,6 The possible use of triple therapy with 
amlodipine, valsartan and HCTZ in a single pill represents 
a step forward in improving the control of hypertension by 
making treatment simpler and thereby improving long-term 
adhesion and treatment persistence.7
This review briefly and concisely explains some phar-
macodynamic and pharmacokinetic aspects of this triple 
therapy and synthesizes the results of the different clinical 
trials carried out using this fixed combination.
Pharmacodynamic profile
Valsartan is a powerful, specific angiotensin II AT
1
 receptor 
antagonist. In hypertensives, administration of a single oral 
dose of valsartan produces a reduction in BP that begins 
2 hours after administration and reaches a peak at 4 to 
6 hours. The antihypertensive effect persists for 24 hours 
after administration. When repeated doses are administered, 
the maximum reduction in BP is usually achieved in 2 to 
4 weeks.8
Amlodipine inhibits the entry of calcium ions to the 
vascular smooth muscle of the resistance arterioles. The 
antihypertensive mechanism of action of amlodipine is 
due to a direct relaxant effect on the vascular smooth muscle, 
causing reductions in peripheral vascular resistance and BP. 
These effects are dependant on the movement of extracellular 
calcium ions to the interior of smooth muscle cells through 
specific ion channels. After administration of therapeutic 
doses to hypertensives, amlodipine causes vasodilation that 
induces a reduction in BP levels with no significant changes 
in the heart rate or plasma catecholamine levels. In hyper-
tensive patients with normal kidney function, therapeutic 
doses of amlodipine are associated with a reduction in renal 
vascular resistance and increased glomerular filtration and 
renal plasma flow, with no modifications in the filtration rate 
or proteinuria.8
HCTZ is a diuretic that reduces the reabsorption of electro-
lytes in the renal tubule, increasing the excretion of sodium and 
chloride and, consequently, increasing plasma renin activity and 
aldosterone secretion, increasing urinary potassium loss and 
reducing serum potassium.8 Currently, no specifically designed 
studies have evaluated the pharmacodynamic characteristics of 
the triple combination. However, in spite of the lack of specific 
pharmacodynamic studies, the use of the fixed combination of 
amlodipine/valsartan/HCTZ is accepted, as the three products 
are all approved by the European Medicines Agency (EMEA) 
to treat hypertension in monotherapy and pharmacodynamic 
studies show no unfavorable interactions.9
Pharmacokinetic profile
The pharmacokinetic characteristics of amlodipine, val-
sartan or HCTZ in monotherapy or in combination at 
f ixed doses (amlodipine/valsartan or valsartan/HCTZ) 
are well known.10,11 The three drugs exhibit linear 
pharmacokinetics.8
Pharmacokinetics of the drugs  
in monotherapy
The absorption of oral amlodipine is practically total and 
plasma concentrations increase gradually to reach a peak at 
6 to 9 hours. Its bioavailability is 64% to 80%, which is not 
modified by food ingestion. Ninety-four percent bonds with 
plasma proteins.12 It is metabolized in the liver by CYP 3A4. 
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The elimination of amlodipine from plasma occurs in two 
phases, with a half-life of 30 to 50 hours. Ten percent of the 
original amlodipine and 60% of amlodipine metabolites are 
excreted in urine.8
The absorption of oral valsartan is approximately 23%, 
reaching a peak at 3 hours. Ninety percent bonds with plasma 
proteins, mainly serum albumin. Valsartan does not transform 
extensively since only approximately 20% of the dose is 
recovered as metabolites. It is mainly eliminated unaltered 
in the feces (83%) and the urine (13%).8 The half-life of 
valsartan is 6 hours.6
The absorption of oral HCTZ is rapid, with a maximum 
serum concentration (C
max
) of approximately 2 hours. The 
increase in mean area under the serum concentration-time 
curve during the dosing interval (AUC) is linear and dose-
dependent within the therapeutic range. The bioavailability is 
65% to 75%. Food ingestion reduces bioavailability by 10% 
and peak concentration by 20%, increasing the maximum 
time from 1.6 hours to 2.9 hours. More than ninety percent 
is eliminated unaltered in the urine.
Pharmacokinetics of the triple 
combination
After oral administration of the fixed combination of 
amlodipine/valsartan/HCTZ in fasting conditions, the peak 
plasma level of valsartan is reached in 3 to 4 hours, that of 
HCTZ in 1 to 3 hours and that of amlodipine in 6 to 9 hours.9 
The elimination half-lives of valsartan, HCTZ and amlodip-
ine are 13 to 23 hours, 10 to 12 hours and 41 to 47 hours, 
respectively.9
The absorption of amlodipine/valsartan/HCTZ is similar 
to the individual administration of each of its components 
in terms of bioequivalence and bioavailability. Five studies 
have evaluated the bioavailability and bioequivalence of 
amlodipine/valsartan/HCTZ and the effect of food inges-
tion on them.8 The VEA489A2305 study analyzed the 
bioequivalence of amlodipine/valsartan/HCTZ at doses of 
5/160/12.5 mg, respectively. With a confidence interval (CI) 
of 90% the ratio of the geometric mean for AUC
0-t
, AUC
0-∞, 
C
max
 was 0.8 to 1.25 indicating that the rate and extent of 
absorption of amlodipine/valsartan/HCTZ are similar to 
administration of each drug in monotherapy. Likewise, the 
VEA489A2306 study, which analyzed the bioequivalence 
of a dose of 5/160/25 mg, respectively, found a similar 
range of bioequivalence. The subsequent VEA489A2105 
and VEA489A2106 studies analyzed the bioequivalence of 
5 and 10 mg of amlodipine in the United States formulation 
versus the Norvasc® formulation, and both studies found a 
range of AUC
0–t
, AUC
0–∞, Cmax of 0.8 to 1.25. Comparison 
between amlodipine/valsartan/HCTZ 10/160/25 mg and 
amlodipine/valsartan/HCTZ 10/160/12.5 mg showed no 
differences in bioequivalence and bioavailability. The com-
bination of amlodipine/valsartan/HCTZ at a maximum dose 
of 10/320/25 mg showed similar linear and dose proportional 
pharmacokinetics to the dose of 5/160/12.5 mg, whose bio-
equivalence was clearly established in the previous trials.
The effect of ingestion on the bioavailability of amlodipine/ 
valsartan/HCTZ 10/320/25 mg at fixed doses in healthy 
subjects was evaluated in the CVEA 489A2310 clinical 
trial, a randomized, open-label, single-dose, two-period 
crossover study. Eighteen subjects were randomized to 
the fixed combination of a single oral dose of amlodipine/ 
valsartan/HCTZ administered under fasting or fed conditions. 
The results showed that the C
max
 of valsartan increased by 
12% and AUC
0–t
, AUC
0–∞, Cmax increased by 14% after inges-
tion in comparison with fasting conditions. The upper limit of 
90% CI for both C
max
 and AUC was between 1.25 and 1.32. 
Likewise, the bioavailability of amlodipine, valsartan and 
HCTZ is similar under fed and fasting conditions following 
a single oral dose administration of 10 mg/320 mg/25 mg 
of the amlodipine/valsartan/HCTZ fixed combination tablet. 
With respect to the pharmacokinetic interaction between 
amlodipine, valsartan and HCTZ, the VEA489A2104 study 
in hypertensive patients found that the addition of valsartan 
to the amlodipine/HCTZ combination increased the AUC of 
HCTZ by 8% and decreased the C
max
 by 17%. The addition 
of valsartan to the amlodipine/HCTZ fixed combination 
increased the AUC and C
max
 of amlodipine by 9% and 10%, 
respectively, with a CI of 80% to 125%.
The addition of HCTZ to the fixed combination of 
amlodipine/valsartan increased the AUC and C
max
 of valsar-
tan by 25% and 22%, respectively, although the geometric 
mean ratios for amlodipine exposure were not within the 
80% to 125% range. Finally, the addition of amlodipine to 
the valsartan/HCTZ fixed combination increased the AUC of 
valsartan by 10% and the C
max
 by 15% and increased the AUC 
of HCTZ by 3% and the C
max
 by 2%, with 90% CI within the 
80%–125% range. In conclusion, there are no pharmacoki-
netic interactions and therefore the safety and efficacy of the 
triple fixed dose combination of amlodipine/valsartan/HCTZ 
is sufficiently demonstrated in phase III efficacy studies.
Special subgroups
Children and adolescents
There are no pharmacokinetic data for people aged 18 
years.
Patient Preference and Adherence 2010:4108
Doménech and Coca Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Elderly patients (65 years)
The peak plasma concentration time of amlodipine is similar 
in young patients and the elderly, although in the elderly 
amlodipine clearance tends to decline, causing an increase 
in AUC of around 70%; therefore, caution should be used 
when increasing the dose.8 The systemic exposure of val-
sartan is slightly higher in the elderly in comparison with 
young people, although no clinical significance has been 
demonstrated. There is little data on the systemic clearance of 
HCTZ, which decreases in both the healthy and hypertensive 
elderly.
Renal failure
The pharmacokinetics of amlodipine are not significantly 
affected by renal failure and therefore patients with a 
glomerular filtration rate 30 mL/minute may receive the 
normal starting dose.8
Liver failure
Patients with liver failure have reduced clearance of amlodip-
ine, increasing the AUC by 40% to 60%. The mean half-life 
of valsartan in patients with mild-to-moderate chronic liver 
disease is double that found in healthy volunteers. Therefore, 
it should be used with caution in patients with liver failure.
Clinical efficacy studies
Clinical trials in patients with hypertension and other cardio-
vascular risk factors or comorbidities have shown the efficacy 
of strategies based on amlodipine,10 valsartan11 or HCTZ in 
the reduction of cardiovascular morbidity and mortality. Two 
completed clinical trials, the VEA A2302 and VEA ABR01 
studies, were designed to evaluate the efficacy and safety 
of amlodipine/valsartan/HCTZ in combination, although 
the VEA ABR01 study found no significant evidence with 
respect to clinical efficacy. The most representative trial 
is the recently published Triple Antihypertensive Therapy 
with Amlodipine, Valsartan and Hydrochlorothiazide: 
A randomized clinical trial (VEA A2302).13
VEA A2302 study13
This was a multinational, randomized, double-blind study 
in parallel groups. Patients aged 18 to 85 years with 
moderate-severe hypertension (grades 2–3) with mean 
sitting diastolic blood pressure (MSDBP)  100 mmHg 
and mean sitting systolic blood pressure (MSSBP) 
 145 mmHg were included. Patients had to discontinue 
antihypertensive treatment for one week, during which 
they received placebo. Patients with severe hypertension 
(MSSBP  180 mmHg or MSDBP  Hg 110 mmHg) were 
randomized immediately to active treatment. Patients who 
did not fulfil inclusion criteria 7 days after ceasing previ-
ous treatment continued with placebo for 2 to 3 weeks and 
were randomized if MSSBP  145 mmHg and MSDBP 
 100 mmHg were achieved. Patients with MSSBP  200 
mmHg or MSDBP  120 mmHg were excluded. Patients 
receiving 4 antihypertensive drugs in the screening 
visit, or 3 antihypertensive drugs with MSSBP/MSDBP 
 140/90 mmHg, or 2 antihypertensive drugs with 
MSSBP/MSDBP  180/110 mmHg were also excluded.
Other exclusion criteria were a history of hypersensitivity 
to one of the three drugs in monotherapy, a history of hyper-
tensive encephalopathy, stroke, transient ischemic accidents, 
myocardial infarction or any other type of revascularization, 
second or third degree heart block, angina pectoris, signifi-
cant arrhythmia or valvular alteration; uncontrolled type 1 or 
type 2 diabetes, hepatic, renal or pancreatic disease or need 
for any other medication that might interfere in BP control.
Of the 4285 patients enrolled in 15 countries, only 
2271 were randomized to double-blind treatment after 
a single-blind placebo run-in period for a maximum of 
4 weeks, followed by active treatment for 8 weeks. After 
receiving instructions on BP self-measurement, patients 
were provided with a semi-automatic OMRON apparatus 
(model HEM705CP) for home determination of systolic 
BP and diastolic BP twice daily during the placebo period. 
Patients with MSSBP  145 mmHg and  200 mmHg 
and MSDBP  100 mmHg and  120 mmHg were 
randomized (1:1:1:1) to one of the four treatment arms: 
amlodipine/valsartan/HCTZ 10/320/25 mg, valsartan/ 
HCTZ 320/25 mg, amlodipine/valsartan 10/320 mg or 
amlodipine/HCTZ 10/25 mg all once daily.
Patients underwent a 2-stage forced-titration period start-
ing with lower doses of study medication for the two first 
weeks post randomization. From the third week to the end 
of the study at 6 weeks, all patients reached the maximum 
dose to which they had been randomized.
The primary study objective was to evaluate the effi-
cacy and safety of the “high-dose” triple combination 
amlodipine/valsartan/HCTZ 10/320/25 mg in comparison 
with each of the components in double therapy (valsartan/
HCTZ 320/25 mg, amlodipine/valsartan 10/320 mg or 
amlodipine/HCTZ 10/25 mg) in patients with severe-
moderate hypertension. The secondary objectives were to 
evaluate the number of patients who achieved MSSBP/
MSDBP  140/90 mmHg, the number of responders for 
diastolic BP (MSDBP  90 mmHg and/or  10 mmHg with 
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respect to baseline DBP values), the number of responders 
for SBP (MSBPP  140 mmHg and/or 15 mmHg with 
respect to baseline SBP, and the reduction in systolic and 
diastolic mean BP by 24 hour ambulatory BP monitoring 
(ABPM).
Of the 2271 randomized patients, 2060 completed the 
study. The main causes of discontinuation in the placebo run-in 
period were not to require the study drug any longer (28.1%), 
abnormal test procedure results (6.9%) and withdrawal of 
consent (5.3%). In the randomized group, the main causes 
of discontinuation were adverse effects (3.1%), withdrawal 
of informed consent (2.5%) and loss to follow-up (1.5%).
There were no differences in baseline characteristics 
between the two groups. Nearly 72% of randomized patients 
were Causcasians and 55% were male, with a mean age of 
53 years (14% aged 65 years). Baseline MSSBP/MSDBP 
was 169.9/106.5 mmHg. Approximately 10% of patients were 
diabetic. Previous hypertensive treatment included angiotensin 
converting enzyme inhibitors in 30.2%, dihydropyridine deriv-
atives in 18.1%, thiazide diuretics in 17.3%, angiotensin II 
receptor blockers in 16.4% and beta-blockers in 12.5%.
Table 1 summarizes the results of the primary objective. 
Significant reductions in MSDBP and MSSBP were observed 
in comparison with baseline values in the four treatment 
arms, although the greatest reductions were observed in the 
amlodipine/valsartan/HCTZ group. The greatest antihyper-
tensive effect was observed from the third week of treatment 
onwards in all treatment arms. Comparison of the antihyper-
tensive efficacy of the four pharmacological combinations 
showed that amlodipine/valsartan/HCTZ 10/320/25 mg 
achieved significantly higher reductions than those obtained 
with valsartan/HCTZ 320/25, amlodipine/valsartan 10/320 
and amlodipine/HCTZ 10/25 (Table 2). These differences 
were maintained after adjustment for race, sex and age.
With respect to the secondary objectives, signif i-
cantly higher proportions of patients treated with triple 
therapy reached overall BP control (defined as MSSBP/
MSDBP  140/90 mmHg), diastolic control rates and systolic 
control rates. Likewise, the rate of responders for both SBP 
and DBP was also significantly higher in patients randomized 
to the triple therapy. Finally, reductions in BP measured by 
ABPM were clinically and statistically higher in the triple 
therapy arm compared with all three dual therapies.
VEA ABR01 study9
This was a multicenter, randomized, parallel double-blind 
study which included hypertensive patients aged 18 years 
in stable treatment with 2 antihypertensive drugs dur-
ing the last two months. The main end point of the study 
was to evaluate the proportion of patients who reached BP 
control after 12 weeks of treatment. Of the 264 patients 
who received amlodipine/valsartan/HCTZ, 61% reached 
the control objective (intention-to-treat). The percentage 
of control was similar in the treatment arms: 43.9% for 
amlodipine/valsartan/HCTZ10/160/12.5 mg and 45.8% for 
amlodipine/valsartan/HCTZ 5/160/25 mg. However, the 
main limitation of this study was that it was not designed to 
compare antihypertensive strategies.9
VAA A2201E1 study9
This was a multicenter, double-blind, open label extension 
study lasting 52 weeks in 2201 patients with mild-moderate 
Table 1 Within-treatment analyses for change from baseline to endpoint in mean sitting BP (ITT population)
Treatment N Mean change from  
baseline (SE)
95% CI for mean  
change from baseline
P value 
Diastolic BP
AML/VAL/HCTZ 10/320/25 571 -24.57 (0.395) (-25.348-23.797) 0.0001*
VAL/HCTZ 320/25 553 -19.40 (0.431) (-20.250-18.558) 0.0001*
AML/VAL 10/320 558 -21.41 (0.394) (-22.186-20.639) 0.0001*
AML/HCTZ 10/25 554 -19.60 (0.407) (-20.399-18.801) 0.0001*
Systolic BP
AML/VAL/HCTZ 10/320/25 571 -39.37 (0.962) (-40.725-38.08) 0.0001*
VAL/HCTZ 320/25 553 -31.81 (0.739) (-33.265-30.362) 0.0001*
AML/VAL 10/320 558 -33.37 (0.660) (-34.668-32.077) 0.0001*
AML/HCTZ 10/25 554 -31.86 (0.710) (-33.264-30.475) 0.0001*
*Indicates statistical significance 0.05.
Data obtained from the VEA A2302 Study.13
Abbreviations: ITT, intention to treat;  AML, amlodipine;  VAL, valsartan; HCTZ, hydrochlorothiazide.
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hypertension who were randomized to receive amlodipine/val-
sartan 2.5/80 mg or 5/80 mg for 8 weeks. The dose was later 
increased to amlodipine/valsartan 5/160 or 10/160 mg, with the 
option of adding HCTZ 12.5 mg if BP control was inadequate. 
However, since the number of patients who required HCTZ was 
far below those who received dual therapy, this study can only 
be used for safety evaluation but does not support the efficacy 
of the triple combination of amlodipine/valsartan/HCTZ.9
Safety and tolerability studies
Although a reasonable number (1789) of patients have been 
treated with the triple combination of amlodipine/valsartan/
HCTZ, most information on safety and tolerability comes 
from the VEA A2302 study.13 The number of patients 
treated with high doses of this combination or treated for 
more than 6 months is limited. There are also few data 
on people aged 65 years and subgroups such as type 
1 diabetics, badly controlled type 2 type diabetics, and 
patients with pre-existing heart disease or renal failure 
(creatinine 1.5).13
In the VEA A2302 study, the frequency of patients 
with 1 adverse effect (AE) was similar in the four treat-
ment arms, with a proportion of between 45% and 48%. 
Most adverse effects were classified as mild-moderate. The 
Table 2 Between-treatment comparisons for change from baseline to endpoint in mean sitting BP (MSBP) (mmHg)
Treatment LSM change from 
baseline
LSM difference in change  
from baseline (SE)
P value Hochberg adjusted 
P value
Diastolic BP
AML/VAL/HCTZ 10/320/25 -24.74 0.0001*
VAL/HCTZ 320/25 -19.69 -5.05 (0.539) 0.0001
AML/VAL 10/320 -21.49 -3.25 (0.537) 0.001+
AML/HCTZ 10/25 -19.46 -5.28 (0.539) 0.0001
Systolic BP
AML/VAL/HCTZ 10/320/25 -39.68 0.0001*
VAL/HCTZ 320/25 -32.04 -7.64 (0.848) 0.0001
AML/VAL 10/320 -33.5 -6.18 (0.846) 0.001**
AML/HCTZ 10/25 -31.48 -8.20 (0.848) 0.0001
Notes: The Hochberg adjusted P values are based on the maximum P value for the three comparisons in MSDBP and the maximum P value for the three comparisons in 
MSSBP.
*Indicates statistical significance P  0.05.
**Maximum P values of the three comparisons.
Adapted with permission from Calhoun DA, Lacourciere Y, Chiang TY, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan and hydrochlorothiazide: A random-
ized clinical trial. Hypertension. 2009;54:32–39.13 Copyright © 2009 Lippincott, Williams & Wilkins.
Abbreviations: LSM, least squares mean;  AML, amlodipine;  VAL, valsartan; HCTZ, hydrochlorothiazide.
Table 3 Adverse events, regardless of study drug relationship, by preferred term and treatment
  AML/VAL/HCTZ 
10/320/25 mg (n = 582)
VAL/HCTZ  
320/25 mg (n = 559)
AML/VAL  
10/320 (n = 566)
AML/HCTZ  
10/25 mg (n = 561)
Total  
(n = 2268)
Preferred term N (%) N (%) N (%) N (%) N (%)
Any preferred term 263 (45.2) 253 (45.3) 254 (44.9) 271 (48.3) 1041 (45.9)
Dizziness 45 (7.7) 39 (7) 13 (2.3) 22 (3.9) 119 (5.2)
Peripheral edema 26 (4.5) 5 (0.9) 48 (8.5) 50 (8.9) 129 (5.7)
Headache 25 (4.3) 30 (5.4) 28 (4.9) 39 (7) 122 (5.4)
Dyspepsia 13 (2.2) 5 (0.9) 6 (1.1) 2 (0.4) 26 (1.1)
Fatigue 13 (2.2) 15 (2.7) 12 (2.1) 8 (1.4) 48 (2.1)
Muscle spasms 13 (2.2) 7 (1.3) 7 (1.2) 5 (0.9) 32 (1.4)
Back pain 12 (2.1) 13 (2.3) 5 (0.9) 12 (2.1) 42 (1.9)
Nasopharyngitis 12 (2.1) 13 (2.3) 13 (2.3) 12 (2.1) 50 (2.2)
Nausea 12 (2.1) 7 (1.3) 10 (1.8) 12 (2.1) 41 (1.8)
Reproduced with permission from Calhoun DA, Lacourciere Y, Chiang TY, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan and hydrochlorothiazide: 
A randomized clinical trial. Hypertension. 2009;54:32–39.13 Copyright © 2009 Lippincott, Williams & Wilkins.
Abbreviations: AML, amlodipine;  VAL, valsartan; HCTZ, hydrochlorothiazide.
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most common adverse effects (Table 3) were peripheral 
edema (5.7%), headache (5.4%) and dizziness (5.2%). 
Dizziness occurred more frequently in the triple therapy 
(7.7%) and in the dual combination of valsartan/HCTZ 
(7%) compared with the dual combinations of amlodipine/
valsartan (2.3%) or amlodipine/HCTZ (3.9%). Peripheral 
edema, however, was more common in patients receiving 
amlodipine/HCTZ (8.9%) or amlodipine/valsartan (8.5%) 
than in those treated with the triple combination (4.5%) or 
valsartan/HCTZ (0.9%) (Table 4). Three percent of adverse 
effects were classified as severe, and the distribution was 
similar in all four treatment arms. Adverse effects poten-
tially associated with reductions in BP were very infrequent. 
Hypotension was most frequently reported in patients 
receiving triple therapy (1.5%) and the valsartan/HCTZ 
(1.4%) combination. Other symptoms, such as fainting 
(1%), postural instability or orthostatic hypotension were 
infrequent.9
In the longest study (2201E1) the most common adverse 
effects reported were peripheral edema, nasopharyngitis, diz-
ziness, headache and back pain. The incidence of edema was 
17% for the high dose combination and 9.7% for the low dose 
combination.9 No deaths were reported in any of the stud-
ies. Seventy-six percent of patients reporting severe adverse 
effects required hospitalization.13 Analytical alterations were 
consistent with the known biochemical effects of amlodipine, 
valsartan or HCTZ. There was an increase in blood urea in all 
arms, which was greater in the triple combination and in the 
valsartan/HCTZ combination. Increased creatinine, uric acid 
and calcium were observed in patients who received HCTZ. 
Serum potassium decreased in all arms including HCTZ; the 
reduction was greatest in the amlodipine/HCTZ combination 
(-0.39 mmol/L) and smallest in the amlodipine/valsartan/
HCTZ (-0.16 mmol/L) and valsartan/HCTZ (-0.08 mmol/L) 
combinations.9
In general, there was a lower incidence of adverse effects 
in people aged 65 years than in younger people in the triple 
combination group, although only 14% of patients included 
in the VEA A2302 study were aged 65 and only 14 patients 
(2.2%) were aged 75 years.9 Only 3% of patients in the VEA 
A2302 trial discontinued the study, mainly due to dizziness 
and hypotension, with an incidence of 1% and 0.7% in the 
triple and dual combination groups, respectively, effects 
that were attributed a priori to the greater antihypertensive 
efficacy of the triple combination with respect to the dual 
combinations.
There are no data on the amlodipine/valsartan/HCTZ 
fixed combination in pregnant women, although according 
to the recommendations for each drug in monotherapy, triple 
therapy is not advised in the first trimester of gestation and is 
contraindicated in the second and third trimesters.9
Future perspectives of triple  
fixed combinations
Currently, although there are a large number of antihyper-
tensive drugs and fixed combinations of two drugs, there are, 
in general, no large differences in their efficacy in reducing 
BP when administered in monotherapy. Only 30% to 40% 
of hypertensive patients achieve BP control with a single 
drug.14 Many clinical trials on the efficacy of hypertensive 
treatment have shown the necessity to associate different 
antihypertensive drugs to reach BP control according to 
total cardiovascular risk. This evidence is collected in the 
2007 Guidelines of the European Society of Hypertension/
European Society of Cardiology, and is confirmed and 
reinforced by the very-recent reappraisal of guidelines by 
the European Society of Hypertension.15 The ESH/ESC 
guidelines promote the use of fixed combinations as the 
frontline antihypertensive strategy in patients with very high 
BP or in those with high cardiovascular risk, in whom a rapid 
reduction in BP is desirable.15
The vast majority of essential hypertensive patients 
will require two or more antihypertensive drugs to achieve 
blood pressure targets.16 In addition, the recent ESH reap-
praisal of the European guidelines states that the best 
combinations for hypertension treatment are combinations 
of agents blocking the rennin-angiotensin system with 
thiazide diuretics or calcium channel blockers, and the 
combination of all three drugs when needed. Therefore, 
the use of these three components in a single pill taken in 
the morning seems a reasonable choice for many patients 
Table 4 Comparison of occurrence of peripheral edema between 
treatment groups
Treatment 
 comparison  
(A vs B)
Treatment A  
n/N (%) 
Treatment B  
n/N (%) 
P value 
 
AML/VAL/HCTZ 
10/320/25 vs 
VAL/HCTZ 320/25
26/582 (4.5) 5/559 (0.9) 0.0002
AML/VAL/HCTZ 
10/320/25 vs 
 AML/VAL 10/320
26/582 (4.5) 48/566 (8.5) 0.0057
AML/VAL/HCTZ 
10/320/25 vs 
AML/HCTZ 10/25
26/582 (4.5) 
 
50/561 (8.9) 
 
0.0029 
 
Data obtained from the VEA A2302 Study.13
Abbreviations: AML, amlodipine;  VAL, valsartan; HCTZ, hydrochlorothiazide.
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with moderate-severe high risk hypertension. An alpha or 
beta-blocker may be added to this baseline strategy when 
needed due to comorbidities or to achieve blood pressure 
control.15 The possibility of giving three drugs in a single 
tablet instead of three tablets will improve adherence to 
the therapeutic strategy, the quality of life and treatment 
persistence in the long term. In addition, the cost of the 
combination is often less expensive than buying each drug 
individually.17
Triple combination therapy with amlodipine/valsartan/
HCTZ in a single tablet should be administered once daily 
with or without food. The highest recommended dose 
is 10/320/25 mg.8 It is contraindicated in patients with 
severe renal failure (creatinine clearance 30 mL/min), 
severe liver failure, during the second and third trimesters 
of pregnancy, and in cases of refractory hypokalemia, 
hyponatremia, hypercalcemia and symptomatic hyper-
uricemia. Caution is recommended in patients with mild-
moderate liver failure, heart failure and coronary disease 
and in elderly patients in whom the maximum dose of 
10/320/25 mg is not recommendable. There are no data 
to support the indication of amlodipine/valsartan/HCTZ 
in pediatric patients.8 Finally, drug interactions have not 
been explicitly evaluated, although the interactions known 
for the individual components are attributed to the triple 
combination.8 Logically, the triple fixed-dose combina-
tion of amlodipine/valsartan/HCTZ may increase the 
hypotensive effects of other antihypertensive drugs the 
patient may be taking.8
Summary and conclusions
The prevalence of hypertension in Europe is approximately 
20% to 30% in the third/fourth decade of life and increases 
to 70% in people aged 65 years.9 Most patients require 
pharmacological combinations to achieve BP control.9 The 
combination of three drugs with synergistic and comple-
mentary mechanisms of action is a reasonable option for the 
management and control of moderate to severe hypertension. 
This article has reviewed the current evidence on the antihy-
pertensive efficacy and safety of the triple combination of 
amlodipine/valsartan/HCTZ at both low and maximum doses. 
The efficacy of the triple combination is superior to that of its 
components in monotherapy or in dual combination. The toler-
ability and safety are good with only mild to moderate adverse 
effects in most cases, whose frequency is similar or inferior to 
that of its components in monotherapy. The main benefit of 
this triple combination in one tablet is to improve treatment 
adherence and compliance in order to achieve the therapeutic 
objective rapidly and efficiently.12 It is proven that delaying 
BP control by strategies of staggered dose increases is a risk 
factor for cardiovascular events in comparison with the initial 
use of combinations.16
In conclusion, the availability of a combination of three 
antihypertensive drugs in a single tablet contributes additional 
advantages to dual combinations, allowing more rapid and 
effective BP control in patients with moderate-severe hyper-
tension or high cardiovascular risk. This is undoubtedly the 
right path to increase treatment adherence, improve compli-
ance and reduce the morbidity and mortality associated with 
inadequate BP control.
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